Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

v3.20.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
COSTS AND EXPENSES:    
Research and development $ 2,616,337 $ 2,308,397
General and administrative 1,342,318 1,321,415
Total costs and expenses 3,958,655 3,629,812
LOSS FROM OPERATIONS (3,958,655) (3,629,812)
OTHER INCOME (EXPENSE):    
Loss on revaluation of derivative warrants 0 (4,000)
Interest income, net 1,047 12,171
Total other income, net 1,047 8,171
NET LOSS $ (3,957,608) $ (3,621,641)
BASIC AND DILUTED NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS PER COMMON SHARE $ (0.42) $ (0.76)
SHARES USED IN COMPUTING BASIC AND DILUTED NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS PER COMMON SHARE 9,389,661 4,773,500